Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) announced that on October 1, 2025 its Compensation Committee granted inducement awards under the 2023 Inducement Option Plan to seven new employees.

The awards consist of 122,250 nonstatutory stock options with an exercise price of $9.20 per share (closing price on October 1, 2025). Options vest over four years: 25% at the one-year anniversary and the remainder monthly over 36 months, subject to continued service, and are governed by the plan and option agreements.

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on October 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 122,250 shares of common stock to seven (7) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price equal to $9.20 per share, the closing price of the Company’s common stock on October 1, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Contacts

Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

What did KURA announce on October 3, 2025 about inducement grants?

KURA disclosed inducement grants of 122,250 nonstatutory stock options to seven new employees, announced Oct 3 for grants dated Oct 1, 2025.

What is the exercise price and vesting schedule for the KURA inducement options?

Exercise price is $9.20 per share; vesting is 25% after one year then monthly over the next 36 months.

How many employees received KURA inducement awards and under which plan?

Seven new employees received awards under KURA's 2023 Inducement Option Plan, as amended.

Do KURA inducement grants affect current shareholders immediately?

No immediate dilution occurs until options are exercised; the PR does not state outstanding share count or dilution percentage.

Are the KURA inducement options conditional on continued employment?

Yes; options vest subject to each new employee's continued service through applicable vesting dates.